Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 30 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
ERUDITE PHARMA from Kortrijk, company number BE0740537194, closed financial year 2025 with a result of € -17,585 after tax. For that financial year ERUDITE PHARMA recorded a gross margin of € 194,964 and equity of € 340,033. Compared with financial year 2024, the result moved from € -6,227 to € -17,585. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.
€ 340,033
▼ 5% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -17,585
▼ 182 % more loss than in 2024
Profit after tax over the fiscal year.
€ 68,300
▲ 11% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -390,847.
People and assets in 2025
1.6
Average over the fiscal year, from the social balance sheet.
€ 138,632
▲ 10% vs 2024
€ 86,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 590,808
▼ 9% vs 2024
€ 56,364 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.
€ 71,006
▲ 31% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 12,906
▲ 75% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 128,697 | € 164,147 | € 193,438 | € 194,964 | ▲ 1% |
| Profit after taxes | € -95,861 | € -7,942 | € -6,227 | € -17,585 | ▼ € 11,357 |
| Equity | € 371,787 | € 363,845 | € 357,618 | € 340,033 | ▼ 5% |
| Total debts | € 1,245,867 | € 1,171,635 | € 1,107,937 | € 1,063,606 | ▼ 4% |
| Cash | € 136,757 | € 51,555 | € 61,679 | € 68,300 | ▲ 11% |
| Land & buildings | € 1,026,204 | € 1,044,956 | € 1,011,692 | € 959,872 | ▼ 5% |
| Retained profit | € -359,094 | € -367,035 | € -373,263 | € -390,847 | ▼ € 17,585 |
| Bank debt | € 753,270 | € 697,891 | € 646,832 | € 590,808 | ▼ 9% |
| Balance sheet total | € 1,617,654 | € 1,535,480 | € 1,465,555 | € 1,403,639 | ▼ 4% |
| Employees (FTE) | 2.2 | 1.6 | 1.6 | 1.6 |
Key figures of ERUDITE PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ERUDITE PHARMA?
What happened at ERUDITE PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 17,585. Source: NBB ↗
- New establishment in Kortrijk. KBO
- Start of the company according to the CBE. KBO
In short
From € 95,861 loss in 2022 to € 17,585 loss in 2025.
On average € 121,900 of value added per employee in 2025.
A new publication or filing at ERUDITE PHARMA? We notify you, reason included.
Follow ERUDITE PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind ERUDITE PHARMA are LISCICOM BVBA, Charles Declerck, Louis Declerck and Augustin Declerck. Charles Declerck is also behind Medeca and Trenker HoldCo. Louis Declerck is also behind T.DIFFUSION, NUTRIPHYT, TRENKER NUTRITION, ERUDITE and LISCICOM.
Directors
According to the 2025 annual accounts
Director · represented by Ineke Demuylder
Louis Declerck
Director
Also active at: T.DIFFUSION, NUTRIPHYT, TRENKER NUTRITION, ERUDITE, LISCICOM, Erudite.Health, Trenker HoldCo
Augustin Declerck
Director
Establishments
Establishment units
Physical locations of this company
Burgemeester Gillonlaan(Kor) 81
8500 Kortrijk
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0740.537.194
- VAT number
- BE 0740.537.194
- Registered office
- Burgemeester Gillonlaan(Kor) 81, 8500 Kortrijk
- Names & denominations
- ERUDITE PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 27 December 2019
- Peppol
- Active · Active since 28 May 2025
- Activities · NACE
Detailhandel in farmaceutische producten